| Primary |
| Product Used For Unknown Indication |
20.8% |
| Drug Use For Unknown Indication |
19.2% |
| Multiple Sclerosis |
6.8% |
| Off Label Use |
5.6% |
| Kawasaki's Disease |
4.8% |
| Pain |
4.8% |
| Myasthenia Gravis |
4.4% |
| Foetal Exposure Timing Unspecified |
3.2% |
| Immunodeficiency Common Variable |
3.2% |
| Lung Infection |
3.2% |
| Polyneuropathy |
2.8% |
| Primary Immunodeficiency Syndrome |
2.8% |
| Thrombocytopenia |
2.8% |
| Aplasia Pure Red Cell |
2.4% |
| Congo-crimean Haemorrhagic Fever |
2.4% |
| Guillain-barre Syndrome |
2.4% |
| Multifocal Motor Neuropathy |
2.4% |
| Autoimmune Haemolytic Anaemia |
2.0% |
| Hypogammaglobulinaemia |
2.0% |
| Idiopathic Thrombocytopenic Purpura |
2.0% |
|
| Pyrexia |
9.8% |
| Vomiting |
9.8% |
| Cardiac Arrest |
6.1% |
| Haemoglobin Decreased |
6.1% |
| Unresponsive To Stimuli |
6.1% |
| Chest Pain |
4.9% |
| Drug Ineffective |
4.9% |
| Headache |
4.9% |
| Malaise |
4.9% |
| Tachycardia |
4.9% |
| Thrombocytopenia |
4.9% |
| Anaphylactic Reaction |
3.7% |
| Body Temperature Normal |
3.7% |
| Chills |
3.7% |
| Death |
3.7% |
| Epilepsy |
3.7% |
| Meningitis Aseptic |
3.7% |
| Nausea |
3.7% |
| Neutropenia |
3.7% |
| Pain |
3.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
27.9% |
| Multiple Sclerosis |
14.5% |
| Lung Infection |
5.9% |
| Off Label Use |
5.0% |
| Product Used For Unknown Indication |
4.8% |
| Prophylaxis |
4.8% |
| Allergy Prophylaxis |
4.1% |
| Panel-reactive Antibody |
4.1% |
| Renal Transplant |
4.1% |
| Myasthenia Gravis |
3.7% |
| Acute Hiv Infection |
3.0% |
| Intentional Use For Unlabeled Indication |
3.0% |
| Lewis-sumner Syndrome |
2.8% |
| Polyneuropathy |
2.2% |
| Aplasia Pure Red Cell |
1.9% |
| Autoimmune Haemolytic Anaemia |
1.9% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Dermatomyositis |
1.7% |
| Hiv Infection |
1.5% |
| Kawasaki's Disease |
1.5% |
|
| Hepatitis B Dna Assay Positive |
15.1% |
| Cardiac Arrest |
11.6% |
| Pyrexia |
6.8% |
| Neutropenia |
6.2% |
| Haemoglobin Decreased |
5.5% |
| Hypertension |
5.5% |
| Peripheral Embolism |
5.5% |
| Respiratory Tract Infection |
5.5% |
| Pulmonary Embolism |
4.8% |
| Acute Pulmonary Oedema |
3.4% |
| Dizziness |
3.4% |
| Multiple Sclerosis |
3.4% |
| Nail Disorder |
3.4% |
| Urticaria |
3.4% |
| Chest Pain |
2.7% |
| Hepatitis B Core Antibody Positive |
2.7% |
| Hepatitis B Surface Antibody Positive |
2.7% |
| Nausea |
2.7% |
| Plasma Cell Myeloma |
2.7% |
| Respiratory Disorder |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.4% |
| Infection Prophylaxis |
11.6% |
| Chemotherapy |
7.4% |
| Bone Marrow Conditioning Regimen |
4.1% |
| Diabetes Mellitus |
4.1% |
| Multiple Myeloma |
4.1% |
| Stem Cell Transplant |
4.1% |
| Chronic Lymphocytic Leukaemia |
3.3% |
| Hypertension |
3.3% |
| Neutropenia |
3.3% |
| Pain |
3.3% |
| Prophylaxis |
3.3% |
| Anticoagulant Therapy |
2.5% |
| Local Anaesthesia |
2.5% |
| Pneumonia |
2.5% |
| Renal Transplant |
2.5% |
| Gastritis Prophylaxis |
1.7% |
| Hypogammaglobulinaemia |
1.7% |
| Immunodeficiency |
1.7% |
| Multiple Sclerosis |
1.7% |
|
| Headache |
17.4% |
| Herpes Zoster |
13.0% |
| Petit Mal Epilepsy |
13.0% |
| Myelodysplastic Syndrome |
8.7% |
| Convulsion |
4.3% |
| Epilepsy |
4.3% |
| Fall |
4.3% |
| General Physical Health Deterioration |
4.3% |
| Hypertonia |
4.3% |
| Incorrect Dose Administered |
4.3% |
| Lip Injury |
4.3% |
| Refractory Cytopenia With Multilineage Dysplasia |
4.3% |
| Stomatitis |
4.3% |
| Unresponsive To Stimuli |
4.3% |
| Weight Decreased |
4.3% |
|
